LoginRegister

    Cadila gets USFDA nod for generic drug to treat Parkinson

    Written by Ruby Khatun Khatun   |  

    New Delhi: Cadila Healthcare said it has received approval from the US health regulator to market Pramipexole Dihydrochloride extended-release tablets, used for treating Parkinson's disease, in the American market.


    The company's subsidiary, Zydus Pharmaceuticals (USA) Inc, has received the final approval from the USFDA to market Pramipexole Dihydrochloride extended-release tablets in strengths of 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg, Cadila Healthcare said in a statement.

    The drug is indicated to treat signs and symptoms of Parkinson's disease (PD).

    The Ahmedabad-based firm also received final approval from the USFDA to market Nitrofurantoin Capsules USP, used for treating acute uncomplicated urinary tract infections, in the US market.

    Both the drugs will be manufactured at Zydus group's formulations manufacturing facility at Moraiya, Ahmedabad.
    American marketapprovalCadilaCadila Healthcaregeneric drugmarketNitrofurantoin Capsules USPParkinsonParkinson's diseasepharma newsPramipexole DihydrochloridePramipexole Dihydrochloride extended-release tabletsurinary tract infectionsUS marketUSFDAZydus Pharmaceuticals
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X